. Author manuscript; available in PMC: 2018 Jul 9.

Published in final edited form as: Clin Immunol. 2018 Mar 5;191:10–20. doi: 10.1016/j.clim.2018.03.002

Table 2.

T-cell function during and following treatment with tofacitinib.

	Median (range)

	Baseline	Day 15	Day 29	Day 14(BR/)post-treatment	Day 28(BR/)post-treatment
CD107a + CD8 T cells following stimulation with anti-CD3/CD28 (%)	4.42 (0.87–20.80)	2.77^*** (0.50–10.78)	3.72 (0.59–15.20)	5.01^† (0.70–18.24)	4.43 (0.44–18.21)
IFN-γ + CD8 T cells following stimulation with anti-CD3/CD28 (%)	8.54 (3.29–23.11)	5.73^*** (2.17–19.11)	7.45^* (1.89–22.11)	7.76 (1.42–24.18)	7.47^* (1.97–23.16)
IFN-γ-producing cells following stimulation with anti-CD3 (SFCs/10⁶ PBMCs)	1784 (1118–1920)	1785 (967–2000)	1741 (757–2000)	1745 (1332–2000)	1780 (966–2000)
IFN-γ-producing cells following stimulation with CMV antigen (SFCs/10⁶ PBMCs)	834 (199–1869)	777^** (181–1928)	848^* (166–1884)	909 (138–2000)	960 (99–2000)

Test statistics are based on log-transformed data.

CD, cluster of differentiation; CMV, cytomegalovirus; IFN-γ, interferon-gamma; PBMC, peripheral blood mononuclear cell; SFC, spot-forming cell.

p < 0.05,

^**

p < 0.001,

^***

p < 0.0001 compared with baseline,

^†

p < 0.05 compared with Day 29.